AU2002359202C1 - Pregnane steroids for use in the treatment of CNS disorders - Google Patents

Pregnane steroids for use in the treatment of CNS disorders Download PDF

Info

Publication number
AU2002359202C1
AU2002359202C1 AU2002359202A AU2002359202A AU2002359202C1 AU 2002359202 C1 AU2002359202 C1 AU 2002359202C1 AU 2002359202 A AU2002359202 A AU 2002359202A AU 2002359202 A AU2002359202 A AU 2002359202A AU 2002359202 C1 AU2002359202 C1 AU 2002359202C1
Authority
AU
Australia
Prior art keywords
hydroxy
3beta
5alpha
pregnan
3alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002359202A
Other languages
English (en)
Other versions
AU2002359202B2 (en
AU2002359202A1 (en
Inventor
Torbjorn Backstrom
Inga-Maj Johansson
Per Lundgren
Ming-De Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine AB
Original Assignee
Umecrine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine AB filed Critical Umecrine AB
Publication of AU2002359202A1 publication Critical patent/AU2002359202A1/en
Publication of AU2002359202B2 publication Critical patent/AU2002359202B2/en
Priority to AU2009201956A priority Critical patent/AU2009201956B2/en
Priority to AU2009201951A priority patent/AU2009201951A1/en
Application granted granted Critical
Publication of AU2002359202C1 publication Critical patent/AU2002359202C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002359202A 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of CNS disorders Ceased AU2002359202C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2009201956A AU2009201956B2 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders
AU2009201951A AU2009201951A1 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0104423-9 2001-12-27
SE0104423A SE0104423D0 (sv) 2001-12-27 2001-12-27 Pregnane steroids and their use in the treatment of CNS disorders
PCT/SE2002/002423 WO2003059357A1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of cns disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2009201956A Division AU2009201956B2 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders
AU2009201951A Division AU2009201951A1 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders

Publications (3)

Publication Number Publication Date
AU2002359202A1 AU2002359202A1 (en) 2003-07-30
AU2002359202B2 AU2002359202B2 (en) 2009-02-19
AU2002359202C1 true AU2002359202C1 (en) 2011-03-31

Family

ID=20286518

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2002359202A Ceased AU2002359202C1 (en) 2001-12-27 2002-12-20 Pregnane steroids for use in the treatment of CNS disorders
AU2009201956A Ceased AU2009201956B2 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders
AU2009201951A Abandoned AU2009201951A1 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2009201956A Ceased AU2009201956B2 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders
AU2009201951A Abandoned AU2009201951A1 (en) 2001-12-27 2009-05-18 Pregnane steroids for use in the treatment of CNS disorders

Country Status (10)

Country Link
US (2) US7960367B2 (cg-RX-API-DMAC7.html)
EP (2) EP2275109B1 (cg-RX-API-DMAC7.html)
JP (2) JP2005519893A (cg-RX-API-DMAC7.html)
CN (3) CN101601674A (cg-RX-API-DMAC7.html)
AU (3) AU2002359202C1 (cg-RX-API-DMAC7.html)
CA (1) CA2468248C (cg-RX-API-DMAC7.html)
DK (1) DK1458399T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394639T3 (cg-RX-API-DMAC7.html)
SE (1) SE0104423D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003059357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DK1812009T3 (da) * 2004-11-18 2013-08-05 Umecrine Ab GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser
EP2711372A1 (en) 2006-11-21 2014-03-26 Umecrine AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
JP5687287B2 (ja) 2010-01-14 2015-03-18 ウメクライン ムード エービー 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
RU2667065C2 (ru) 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US10933014B2 (en) * 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
CN110430883A (zh) 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
CN111918657A (zh) * 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050042A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pregnan-3-ol-20-ones

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5439900A (en) * 1993-02-25 1995-08-08 Bukusoglu; Cuneyt Methods and compositions for providing analgesia and enhanced anesthesia
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
PT980381E (pt) 1997-05-02 2003-12-31 Wyeth Corp Sais farmaceuticamente aceitaveis de ester 3-sulfato de 5-alfa-pregn-16-en-3-beta-ol-20-ona com actividade de progesterona e uteis no tratamento de perturbacoes do snc
CN1254342A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 用作孕激素和治疗CNS疾病的5α-孕烷-3β,16α-二醇-20-酮3-硫酸酯的可药用盐
CN1270718C (zh) * 1998-03-11 2006-08-23 托布乔恩·贝克斯托罗姆 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
CZ20011343A3 (cs) 1998-10-13 2002-04-17 American Home Products Corporation Pregnanglukuronidy
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050042A1 (en) * 1997-05-02 1998-11-12 American Home Products Corporation Pregnan-3-ol-20-ones

Also Published As

Publication number Publication date
ES2394639T3 (es) 2013-02-04
US8119619B2 (en) 2012-02-21
AU2009201956B2 (en) 2010-11-25
CN101601674A (zh) 2009-12-16
EP1458399A1 (en) 2004-09-22
CA2468248C (en) 2011-08-16
EP2275109A2 (en) 2011-01-19
JP2010065052A (ja) 2010-03-25
DK1458399T3 (da) 2012-11-12
JP5289281B2 (ja) 2013-09-11
US7960367B2 (en) 2011-06-14
SE0104423D0 (sv) 2001-12-27
US20110098259A1 (en) 2011-04-28
AU2009201956A1 (en) 2009-06-11
CN1607954A (zh) 2005-04-20
WO2003059357A1 (en) 2003-07-24
CN100518741C (zh) 2009-07-29
US20050222099A1 (en) 2005-10-06
JP2005519893A (ja) 2005-07-07
EP2275109A3 (en) 2011-10-12
AU2002359202B2 (en) 2009-02-19
CN101601675A (zh) 2009-12-16
AU2002359202A1 (en) 2003-07-30
EP1458399B1 (en) 2012-08-08
EP2275109B1 (en) 2013-07-24
AU2009201951A1 (en) 2009-06-04
CA2468248A1 (en) 2003-07-24
AU2009201956A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
AU2009201956B2 (en) Pregnane steroids for use in the treatment of CNS disorders
CN1270718C (zh) 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
HUE031390T2 (en) Antagonists of cb1 receptor
WO2009142594A9 (en) The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
US6987101B1 (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
CN1254283A (zh) 孕烷-3-醇-20-酮
Watanabe et al. Stimulation of gastric acid secretion by progesterone metabolites as neuroactive steroids in anesthetized rats
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
US11026953B2 (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 OCT 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 OCT 2010

MK14 Patent ceased section 143(a) (annual fees not paid) or expired